Our Lipid Nanoparticle (LNP) for RNA Delivery services support biotech companies, pharmaceutical research teams, CROs, and academic groups working on mRNA, siRNA, sgRNA, miRNA, circRNA, and other RNA payloads that require controlled intracellular delivery. LNP systems are typically built around four functional lipid classes—ionizable lipid, helper phospholipid, cholesterol, and PEG-lipid—and successful formulation depends on how these components are balanced against RNA size, charge density, structural fragility, desired biodistribution hypothesis, and experimental readout.
Our platform integrates payload review, lipid composition screening, microfluidic formulation, physicochemical characterization, and delivery-focused study planning to help teams move from an RNA concept to a more reproducible research formulation. Whether you are pairing LNP work with a broader drug delivery platform, a dedicated RNA drug delivery system, or upstream RNA production, we structure each program around practical formulation risks rather than generic carrier selection.
Encapsulation and RNA Integrity: RNA payloads differ greatly in length, secondary structure, and chemical modification pattern. mRNA and circular RNA programs often need stronger attention to shear sensitivity, buffer compatibility, and post-formulation integrity, while siRNA and sgRNA programs can face different leakage, ratio, and duplex stability issues. We design formulation workflows that protect RNA during mixing, purification, storage, and downstream assay transfer.
Particle Size and Batch Reproducibility: Small shifts in flow ratio, total flow rate, lipid molar ratio, or solvent composition can change particle size distribution, polydispersity index, and batch-to-batch consistency. For teams screening multiple candidates or comparing biological readouts across studies, reproducible size control is a core requirement rather than a secondary optimization step.
Cell Entry and Endosomal Escape: Strong encapsulation alone does not guarantee useful delivery data. Many LNP projects stall because particles reach cells but release RNA inefficiently, or because a formulation that performs with one payload fails after the cargo is changed. We evaluate formulation logic with attention to cellular uptake, endosomal release, and assay-specific expression or silencing endpoints.
Surface Composition and Targeting Logic: PEG-lipid content, ionizable lipid chemistry, helper lipid choice, and optional surface engineering can affect circulation behavior, protein corona interactions, and tissue or cell-preference trends. For targeted research programs, we help teams decide whether to stay with a standard LNP architecture, explore ligand-assisted designs, or compare LNPs with alternative delivery strategies.
Analytical Readiness: Decision-making in LNP development depends on more than one readout. Size, PDI, zeta potential, encapsulation efficiency, RNA concentration, morphology, stability, and biological response each answer different questions. We organize analytical packages so clients can compare candidates more clearly and avoid advancing formulations with hidden manufacturability or assay-translation problems.
Our LNP for RNA delivery services are designed for teams that need a technically coordinated partner across payload review, formulation development, analytical characterization, and delivery evaluation. We support discovery and research-stage programs involving protein expression, gene silencing, genome editing support studies, and advanced RNA platform assessment.
By combining RNA-aware design logic with formulation and characterization workflows, we help reduce rework between RNA preparation, nanoparticle assembly, and biological testing.
Different RNA cargos do not behave the same during LNP formulation. The matrix below highlights how payload class changes design priorities, common risks, and study-stage fit when selecting or optimizing an LNP for RNA delivery workflow.
| RNA Payload | Primary Delivery Objective | Key LNP Design Priorities | Common Risk Areas | Typical Research Fit |
| mRNA | Achieve efficient cytosolic release for protein expression studies | RNA integrity protection, encapsulation efficiency, size control, endosomal escape, expression-compatible formulation | Shear sensitivity, degradation during handling, variable expression after reformulation, storage instability | Reporter expression, protein replacement research, delivery benchmarking |
| siRNA | Support potent intracellular delivery for gene-silencing studies | Duplex stability, high loading efficiency, controlled particle surface properties, knockdown-oriented screening | Leakage, off-target interpretation caused by inconsistent delivery, formulation-dependent uptake differences | Gene-silencing research, target validation, comparative carrier studies |
| sgRNA / CRISPR RNA | Enable delivery feasibility assessment for genome editing support workflows | Cargo integrity, co-delivery logic where relevant, formulation reproducibility, assay-matched readout design | Cargo complexity, variable editing-associated signal, mismatch between formulation data and functional data | Genome editing support studies, screening programs, platform evaluation |
| circRNA | Preserve structural integrity while enabling sustained translation-oriented studies | Gentle processing conditions, composition compatibility, post-formulation RNA confirmation, stability review | Structural damage during processing, incomplete payload assessment, formulation carryover into assay artifacts | Circular RNA platform research, expression duration comparison, exploratory delivery studies |
| saRNA / long RNA | Build workable formulations for large and demanding RNA architectures | Mixing control, payload integrity, size distribution management, process reproducibility, scalable screening logic | Increased formulation sensitivity, broad size distribution, handling burden, lower operational robustness | Advanced RNA platform development, formulation feasibility and screening |
Figure 1. Schematic diagram of the synthesis of GalNAc-siRNA conjugates. (L, Zhang.; et al, 2022)
Successful LNP projects require more than formulation assembly. This decision matrix summarizes the main analysis categories used to connect lipid composition, process conditions, analytical data, and biological readouts in a practical development workflow.
| Development Analysis Category | Objective | Typical Approaches | Applicable LNP Workflows | Stage Alignment |
| Payload Quality Review | Confirm the RNA is suitable for formulation and downstream interpretation | Concentration check, integrity review, buffer compatibility assessment, impurity risk screening | mRNA, siRNA, sgRNA, circRNA, saRNA projects | Discovery |
| Lipid Composition Screening | Identify lipid ratios or lipid sets that support workable particle formation | Ionizable lipid comparison, PEG-lipid adjustment, helper lipid selection, cholesterol ratio review | Standard and customized LNP formulation programs | Discovery |
| Mixing Parameter Optimization | Improve control over size, PDI, and loading consistency | Flow-rate ratio tuning, total flow-rate variation, solvent-phase adjustment, dilution strategy evaluation | Microfluidic formulation, screening panels, scale-up feasibility review | Discovery / Early Development |
| Encapsulation Assessment | Determine whether the formulation meaningfully retains the RNA payload | Encapsulation efficiency testing, free RNA estimation, comparison before and after purification | All RNA-loaded LNP studies | Discovery / Early Development |
| Surface Property Review | Balance stealth behavior, uptake profile, and targeting-oriented design choices | PEG-lipid level review, zeta potential analysis, ligand feasibility assessment, comparative surface-modification studies | Standard LNPs, ligand-assisted LNPs, targeted screening programs | Early Development |
| Stability Risk Assessment | Reduce loss of performance during storage, handling, and assay use | Storage study design, dilution stress, serum exposure review, repeat measurement of key physical attributes | Candidate ranking, shipment planning, multi-assay workflows | Discovery / Development |
| Biological Translation Review | Link analytical quality to the most relevant functional readout | Uptake study planning, reporter expression analysis, knockdown benchmarking, endpoint selection guidance | mRNA expression, siRNA silencing, genome editing support studies | Development |
This workflow reflects how research teams typically engage our scientists for payload review, formulation development, characterization, and delivery-focused decision support.
Confirm RNA class, sequence or construct information, intended model system, key readout, target cell or tissue hypothesis, and expected deliverables. We also determine whether the project starts from client-supplied RNA or should be integrated with upstream RNA synthesis services.
Review formulation difficulty, likely lipid screening depth, analytical requirements, and any special constraints such as long RNA architecture, targeting ligands, or comparative carrier benchmarking. A project plan is then built around decision-critical data rather than unnecessary testing.
Define starting lipid compositions, mixing conditions, purification strategy, and experimental matrix for screening or focused development. For payload-sensitive programs, we also set handling controls to reduce RNA loss before and during particle assembly.
Execute LNP preparation using controlled mixing workflows, followed by purification or buffer exchange as needed. In-process monitoring is used to maintain consistency and prepare samples for physicochemical analysis and downstream testing.
Measure agreed quality attributes such as size, PDI, zeta potential, and encapsulation performance, then connect those results to the selected biological readout. Where applicable, candidates are ranked based on both formulation quality and functional behavior.
Deliver a structured project package including formulation rationale, analytical data, interpretation notes, and optimization recommendations. This helps clients move efficiently into confirmatory studies, larger follow-up batches, or payload-specific refinement.
Our LNP platform is built for organizations that need scientifically grounded support across RNA preparation, formulation design, analytical qualification, and delivery evaluation. We focus on practical development logic so that LNP candidates are easier to compare, troubleshoot, and advance.
LNP for RNA delivery can support a wide range of research and preclinical development workflows where nucleic acid stability, intracellular access, and controllable formulation behavior are critical. Our services are aligned with the needs of platform teams, discovery groups, and outsourcing managers seeking usable delivery data rather than isolated formulation output.
Whether you need a benchmark LNP composition, a custom formulation screening plan, an analytical package for particle qualification, or a broader RNA delivery workflow connecting RNA production to nanoparticle evaluation, our team can support your program with practical scientific guidance. We work with biotechnology companies, pharmaceutical research teams, CROs, and academic groups to define project scope, recommend fit-for-purpose LNP strategies, and deliver formulation data aligned with demanding research objectives. Contact us to discuss your lipid nanoparticle requirements and explore how our scientists can support your next RNA delivery study.
LNP formulations typically include ionizable lipids for encapsulation efficiency, phospholipids for structural integrity, cholesterol for membrane stability, and PEG-lipids to optimize circulation time and particle size distribution.
The lipid bilayer creates a protective barrier that shields mRNA from nuclease degradation, while the optimized internal environment maintains mRNA structural integrity until cellular delivery is achieved.
Key considerations include target cell type, required expression duration, mRNA size and sequence, delivery route requirements, and specific experimental objectives for protein expression.
Encapsulation efficiency is quantified using fluorescence-based assays and optimized through lipid composition adjustments, process parameter refinement, and formulation technique enhancements.
Loading ......
